In Phase C, individuals will receive ABBV-744 and oral navitoclax. In Phase D, contributors will obtain ABBV-744 and ruxolitinib. Members will obtain treatment till ailment progression or perhaps the members are not able to tolerate the study drugs. 88 These preclinical studies provide paradigms for upcoming clinical trials in AML, https://raela222nyj5.governor-wiki.com/user